Table 2.
Sensitivity at 95% (SE95) and 98% (SE98) specificity of ovarian cancer detection by time between blood donation and diagnosis
| All Ovarian Cancer (N=194) | High-Grade Serous Cancer (N= 75) | |||||
|---|---|---|---|---|---|---|
| Lead time (months) |
# Cases |
SE95 (95% CI) b | SE98 (95% CI) b | # Cases |
SE95 (95% CI) b | SE98 (95% CI) b |
| CA125 | ||||||
| ≤ 6 | 26 | 0.81 (0.60–0.92) | 0.77 (0.56–0.90) | 9 | 0.89 (0.49–0.98) | 0.89 (0.49–0.99) |
| >6–12 | 35 | 0.43 (0.27–0.61) | 0.34 (0.19–0.53) | 12 | 0.33 (0.13–0.63) | 0.33 (0.13–0.64) |
| ≤ 12 | 61 | 0.59 (0.45–0.72) | 0.52 (0.38–0.67) | 21 | 0.57 (0.35–0.77) | 0.57 (0.34–0.77) |
| >12–24 | 75 | 0.27 (0.17–0.39) | 0.20 (0.11–0.33) | 31 | 0.23 (0.11–0.41) | 0.13 (0.05–0.31) |
| ≤ 24 | 136 | 0.41 (0.31–0.52) | 0.35 (0.24–0.46) | 52 | 0.37 (0.24–0.52) | 0.31 (0.18–0.47) |
| >24–36 | 58 | 0.10 (0.04–0.22) | 0.03 (0.01–0.14) | 23 | 0.13 (0.04–0.34) | 0.04 (0.01–0.26) |
| ≤ 36 | 194 | 0.32 (0.24–0.41) | 0.25 (0.17–0.35) | 75 | 0.29 (0.19–0.42) | 0.23 (0.13–0.36) |
| P53 | ||||||
| ≤ 6 | 26 | 0.27 (0.13–0.48) | 0.23 (0.10–0.44) | 9 | 0.33 (0.11–0.67) | 0.33 (0.11–0.68) |
| >6–12 | 35 | 0.14 (0.06–0.31) | 0.11 (0.04–0.28) | 12 | 0.25 (0.08–0.56) | 0.17 (0.04–0.49) |
| ≤ 12 | 61 | 0.20 (0.11–0.33) | 0.16 (0.08–0.30) | 21 | 0.29 (0.13–0.52) | 0.24 (0.10–0.48) |
| >12–24 | 75 | 0.08 (0.03–0.18) | 0.04 (0.01–0.13) | 31 | 0.03 (0.00–0.20) | 0.03 (0.00–0.21) |
| ≤ 24 | 136 | 0.13 (0.08–0.21) | 0.10 (0.05–0.18) | 52 | 0.13 (0.06–0.27) | 0.12 (0.05–0.25) |
| >24–36 | 58 | 0.09 (0.03–0.20) | 0.05 (0.02–0.16) | 23 | 0.09 (0.02–0.30) | 0.09 (0.02–0.30) |
| ≤ 36 | 194 | 0.12 (0.07–0.19) | 0.08 (0.04–0.15) | 75 | 0.12 (0.06–0.23) | 0.11 (0.05–0.22) |
| CTAG1A | ||||||
| ≤ 6 | 26 | 0.27 (0.13–0.48) | 0.19 (0.08–0.40) | 9 | 0.44 (0.17–0.75) | 0.22 (0.05–0.59) |
| >6–12 | 35 | 0.06 (0.01–0.21) | 0.06 (0.01–0.21) | 12 | 0.00 (0.00–0.26) | 0.00 (0.00–0.26) |
| ≤ 12 | 61 | 0.15 (0.07–0.27) | 0.11 (0.05–0.24) | 21 | 0.19 (0.07–0.42) | 0.10 (0.02–0.32) |
| >12–24 | 75 | 0.12 (0.06–0.23) | 0.11 (0.05–0.22) | 31 | 0.16 (0.07–0.34) | 0.16 (0.06–0.35) |
| ≤ 24 | 136 | 0.13 (0.08–0.21) | 0.11 (0.06–0.20) | 52 | 0.17 (0.09–0.31) | 0.13 (0.06–0.27) |
| >24–36 | 58 | 0.05 (0.02–0.15) | 0.03 (0.01–0.14) | 23 | 0.04 (0.01–0.26) | 0.04 (0.01–0.26) |
| ≤ 36 | 194 | 0.11 (0.07–0.17) | 0.09 (0.05–0.16) | 75 | 0.13 (0.07–0.24) | 0.11 (0.05–0.22) |
| CTAG2 | ||||||
| ≤ 6 | 26 | 0.23 (0.10–0.44) | 0.19 (0.08–0.40) | 9 | 0.22 (0.05–0.58) | 0.22 (0.05–0.59) |
| >6–12 | 35 | 0.03 (0.00–0.18) | 0.03 (0.00–0.19) | 12 | 0.00 (0.00–0.26) | 0.00 (0.00–0.26) |
| ≤ 12 | 61 | 0.11 (0.05–0.23) | 0.10 (0.04–0.22) | 21 | 0.10 (0.02–0.32) | 0.10 (0.02–0.32) |
| >12–24 | 75 | 0.11 (0.05–0.21) | 0.05 (0.02–0.15) | 31 | 0.16 (0.07–0.34) | 0.10 (0.03–0.27) |
| ≤ 24 | 136 | 0.11 (0.06–0.19) | 0.07 (0.04–0.15) | 52 | 0.13 (0.06–0.27) | 0.10 (0.04–0.23) |
| >24–36 | 58 | 0.03 (0.01–0.13) | 0.02 (0.00–0.12) | 23 | 0.04 (0.01–0.26) | 0.04 (0.01–0.26) |
| ≤ 36 | 194 | 0.09 (0.05–0.15) | 0.06 (0.03–0.11) | 75 | 0.11 (0.05–0.21) | 0.08 (0.03–0.18) |
| NUDT11 | ||||||
| ≤ 6 | 26 | 0.27 (0.13–0.48) | 0.19 (0.08–0.40) | 9 | 0.33 (0.11–0.67) | 0.22 (0.05–0.59) |
| >6–12 | 35 | 0.06 (0.01–0.21) | 0.03 (0.00–0.19) | 12 | 0.00 (0.00–0.26) | 0.00 (0.00–0.26) |
| ≤ 12 | 61 | 0.15 (0.07–0.27) | 0.10 (0.04–0.22) | 21 | 0.14 (0.05–0.37) | 0.10 (0.02–0.32) |
| >12–24 | 75 | 0.07 (0.03–0.16) | 0.01 (0.00–0.09) | 31 | 0.10 (0.03–0.27) | 0.03 (0.00–0.21) |
| ≤ 24 | 136 | 0.10 (0.06–0.18) | 0.05 (0.02–0.12) | 52 | 0.12 (0.05–0.24) | 0.06 (0.02–0.18) |
| >24–36 | 58 | 0.02 (0.00–0.12) | 0.02 (0.00–0.12) | 23 | 0.00 (0.00–0.15) | 0.00 (0.00–0.15) |
| ≤ 36 | 194 | 0.08 (0.04–0.13) | 0.04 (0.02–0.09) | 75 | 0.08 (0.03–0.18) | 0.04 (0.01–0.13) |
a
Analyses of crude data, unadjusted for matching factors (see Methods section)
b
95% and 98% specificity cut-points were, respectively, 58.01 and 82.59 for CA125, 2.27 and 3.78 for P53-AAb, 1.47 and 1.77 for CTAG2-AAb, 1.58 and 2.03 for CTAG1A-AAb, 1.35 and 1.60 for NUDT11-AAb